BACKGROUND: It is estimated that 37% of the U.S. population is obese. It is unknown how obesity influences the operative and survival outcomes of cytoreductive surgery (CRS)/hyperthermic intraperitoneal chemotherapy (HIPEC) procedures. METHODS: A retrospective analysis of a prospective database of 1,000 procedures was performed. Type of malignancy, performance status, resection status, hospital and intensive care unit stay, comorbidities, morbidity, mortality, and survival were reviewed. RESULTS: A total of 246 patients with body mass index (BMI) of >30 kg/m(2) underwent 272 CRS/HIPEC procedures. Ninety-five (38.6%) were severely obese (BMI > 35 kg/m(2)). A total of 135 (49.6%) procedures were performed for appendiceal and 60 (22.1%) for colon cancer. Median follow-up was 52 months. Both major and minor morbidity were similar for obese and non-obese patients. The 30-day mortality rates for obese and non-obese patients were 1.5 and 2.5%, respectively. Median intensive care unit and hospital stay were 1 and 9 days, regardless of BMI. The 30-day readmission rate was similar between obese and non-obese patients (24.8 vs. 19.4%, p = 0.11). Median survival for low-grade appendiceal cancer (LGA) was 76 months for obese patients and 107 months for non-obese patients (p = 0.32). Survival was worse for severely obese patients (median survival 54 months) versus non-obese patients with LGA (p = 0.04). Survival was similar for obese and non-obese patients with peritoneal surface disease (PSD) from colon cancer or high-grade appendiceal cancer. CONCLUSIONS: Obesity does not influence postoperative morbidity or mortality of patients with PSD, regardless of primary tumor. Severe obesity is associated with decreased long-term survival only in patients with LGA primary disease; however, application of CRS/HIPEC still offers meaningful prolongation of life. Obesity should not be considered a contraindication for CRS/HIPEC procedures.
BACKGROUND: It is estimated that 37% of the U.S. population is obese. It is unknown how obesity influences the operative and survival outcomes of cytoreductive surgery (CRS)/hyperthermic intraperitoneal chemotherapy (HIPEC) procedures. METHODS: A retrospective analysis of a prospective database of 1,000 procedures was performed. Type of malignancy, performance status, resection status, hospital and intensive care unit stay, comorbidities, morbidity, mortality, and survival were reviewed. RESULTS: A total of 246 patients with body mass index (BMI) of >30 kg/m(2) underwent 272 CRS/HIPEC procedures. Ninety-five (38.6%) were severely obese (BMI > 35 kg/m(2)). A total of 135 (49.6%) procedures were performed for appendiceal and 60 (22.1%) for colon cancer. Median follow-up was 52 months. Both major and minor morbidity were similar for obese and non-obesepatients. The 30-day mortality rates for obese and non-obesepatients were 1.5 and 2.5%, respectively. Median intensive care unit and hospital stay were 1 and 9 days, regardless of BMI. The 30-day readmission rate was similar between obese and non-obesepatients (24.8 vs. 19.4%, p = 0.11). Median survival for low-grade appendiceal cancer (LGA) was 76 months for obesepatients and 107 months for non-obesepatients (p = 0.32). Survival was worse for severely obesepatients (median survival 54 months) versus non-obesepatients with LGA (p = 0.04). Survival was similar for obese and non-obesepatients with peritoneal surface disease (PSD) from colon cancer or high-grade appendiceal cancer. CONCLUSIONS:Obesity does not influence postoperative morbidity or mortality of patients with PSD, regardless of primary tumor. Severe obesity is associated with decreased long-term survival only in patients with LGA primary disease; however, application of CRS/HIPEC still offers meaningful prolongation of life. Obesity should not be considered a contraindication for CRS/HIPEC procedures.
Authors: Edward A Levine; John H Stewart; Gregory B Russell; Kim R Geisinger; Brian L Loggie; Perry Shen Journal: J Am Coll Surg Date: 2007-05 Impact factor: 6.113
Authors: Catherine M Olsen; Christina M Nagle; David C Whiteman; David M Purdie; Adèle C Green; Penelope M Webb Journal: Int J Cancer Date: 2008-07-15 Impact factor: 7.396
Authors: P Dubé; L Sideris; C Law; L Mack; E Haase; C Giacomantonio; A Govindarajan; M K Krzyzanowska; P Major; Y McConnell; W Temple; R Younan; J A McCart Journal: Curr Oncol Date: 2015-04 Impact factor: 3.677
Authors: Devon C Freudenberger; Vignesh Vudatha; Andrea N Riner; Kelly M Herremans; Leopoldo J Fernandez; Jose G Trevino Journal: Cancers (Basel) Date: 2022-06-09 Impact factor: 6.575
Authors: Caroline J Rieser; Heather Jones; Lauren B Hall; Eliza Kang; Shannon Altpeter; Amer H Zureikat; Matthew P Holtzman; Andrew Lee; Melanie Ongchin; James F Pingpank; M Haroon A Choudry; David L Bartlett Journal: Ann Surg Oncol Date: 2021-07-05 Impact factor: 5.344